Preparing The Market for Blood-Based Biomarkers

PE: As blood-based biomarkers gain traction for early diagnosis, how is Quanterix preparing the market both clinically and commercially for the integration of these tools into routine care pathways?
Tetrault: So in terms of routine care pathways and blood-based biomarkers. I see it as truly best fit in the clinic, right? We have our routine testing that we go, and we get every year, depending on what age you are, you're marked for certain testing, right? And so, in terms of integration into a routine clinical space, nothing changes for the patient, right? They go in, they have their appointment with their clinician, their clinician orders a blood draw. That blood draw happens behind the scenes. But in terms of integration, Simoa can be integrated into the clinical in a commercial setting, in the sense that it sits in the lab, just like any other piece of information that is used to measure markers in the blood, and it's able to pick up earlier over other platforms, changes that have occurred year over year in a particular patient or a particular cohort, right? So, in terms of integration, nothing changes on the surface for the patient or the clinician. The patient gets prescribed a blood draw. They go they have their blood drawn, the results are provided to the clinician. All behind the scenes, Simoa is powering that precision, the reliability and that ultra sensitivity to ensure that the data that's presented therein is reliable.